Mabpharm Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	646.1	258.23	87.16	55.92	82.88
Revenue	646.1	258.23	87.16	55.92	82.88
Revenue Growth (YoY)	150.20%	196.27%	55.87%	-32.53%	-
Cost of Revenue	72.44	38.83	11.92	15.38	16.78
Gross Profit	573.65	219.39	75.24	40.54	66.11
Selling, General & Admin	511.19	261.98	153.58	118.77	100.06
Research & Development	57.53	75.21	123.21	147.91	263.57
Operating Expenses	568.72	339.07	277.22	266.79	363.63
Operating Income	4.93	-119.67	-201.98	-226.25	-297.52
Interest Expense	-10.81	-10.55	-9.58	-7.19	-2.4
Interest & Investment Income	-	0.51	0.15	0.38	1.95
Currency Exchange Gain (Loss)	-	-1.2	-1.37	-4	-6.59
Other Non Operating Income (Expenses)	10.17	2.69	3.08	25.92	12.89
EBT Excluding Unusual Items	4.29	-128.22	-209.7	-211.14	-291.67
Gain (Loss) on Sale of Investments	-	0.12	0.34	0.04	-
Gain (Loss) on Sale of Assets	-	-	-	0.03	-0.07
Asset Writedown	-0.13	-	-	-	-
Other Unusual Items	-	0.16	-	0.24	-
Pretax Income	4.16	-127.95	-209.36	-210.82	-291.74
Income Tax Expense	-52.97	-	-	-	-
Earnings From Continuing Operations	57.13	-127.95	-209.36	-210.82	-291.74
Net Income	57.13	-127.95	-209.36	-210.82	-291.74
Net Income to Common	57.13	-127.95	-209.36	-210.82	-291.74
Shares Outstanding (Basic)	5,713	4,124	4,124	4,124	4,124
Shares Outstanding (Diluted)	5,713	4,124	4,124	4,124	4,124
Shares Change (YoY)	38.54%	-	-	-	-
EPS (Basic)	0.01	-0.03	-0.05	-0.05	-0.07
EPS (Diluted)	0.01	-0.03	-0.05	-0.05	-0.07
Free Cash Flow	-	-30.24	38.35	-182.01	-348.14
Free Cash Flow Per Share	-	-0.01	0.01	-0.04	-0.08
Gross Margin	88.79%	84.96%	86.32%	72.50%	79.76%
Operating Margin	0.76%	-46.34%	-231.74%	-404.61%	-358.97%
Profit Margin	8.84%	-49.55%	-240.19%	-377.01%	-352.00%
Free Cash Flow Margin	-	-11.71%	44.00%	-325.50%	-420.04%
EBITDA	58.66	-65.94	-150.13	-183.68	-262.78
EBITDA Margin	9.08%	-25.54%	-172.24%	-	-
D&A For EBITDA	53.73	53.73	51.86	42.57	34.74
EBIT	4.93	-119.67	-201.98	-226.25	-297.52
EBIT Margin	0.76%	-46.34%	-231.74%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.